| |||||||||||||||
| The Ins2-TFRC/OVA (commonly referred to as RIP-mOVA) line 296-1B transgene is strongly expressed in pancreatic beta cells and kidney proximal tubular cells and weakly expressed in testes. This transgenic model has been used to study ectopic expression in the thymus and for assessing the requirements for peripheral deletion. | |||||||||||||||
- Description
- Disease & phenotype
- Genes & alleles
- Genotyping
- Health & care
- References
- Pricing & purchasing
- Terms of use
Description
Strain Information
Former Names C57BL/6-Tg(Ins2-TFRC/OV)296Wehi/WehiJ (Changed: 01-FEB-07 ) Type Mutant Strain; Transgenic; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Mating System +/+ sibling x Hemizygote (Female x Male) 16-APR-08 Species laboratory mouse H2 Haplotype b Generation N20+N1F16 (28-AUG-12)
Generation DefinitionsDonating Investigator William Heath, The Walter and Eliza Hall Institute Appearance
black
Related Genotype: a/aDescription
Ins2-TFRC/OVA (commonly referred to as RIP-mOVA) line 296-1B hemizygote transgenic mice are viable, fertile, normal in size and do not display any gross physical or behavioral abnormalities. Immunohistochemical analysis detects strong expression in pancreatic beta cells and kidney proximal tubular cells and weak expression in testes.When C57BL/6-Tg(Ins2-TFRC/OVA)296Wehi/WehiJ is mated to C57BL/6-Tg(TcraTcrb)1100Mjb/J (commonly referred to as OT-1 and recognizes OVA specific T-cells, Stock No. 003831) thymic deletion of OT-1 cells is observed in double transgenic mice, suggesting very low levels of thymic expression. OVA specific CD-8+ T-cells activated by cross presentation infiltrate the pancreas causing beta cell destruction resulting in diabetes. However, these cells do not infiltrate the kidney.
Proliferating OT-1 T-cells appeared specifically in the lymph nodes draining the pancreas (PLN's) and kidney (RLN's) on day 3 after adoptive transfer of naive OT-1 cells into adult C57BL/6-Tg(Ins2-TFRC/OVA)296Wehi/WehiJ hosts. In contrast, no proliferating cells were detected in the PLN's after introduction into 10-d-old recipients, although they were observed in significant numbers in the RLNs of these animals.
This transgenic model has been used to study ectopic expression in the thymus and for assessing the requirements for peripheral deletion.
Development
The fusion transgene TFRC/OVA is under the control of the rat insulin promoter (Ins2) and encodes the first 118 residues of the human transferrin receptor (TFRC), which includes the cytoplasmic tail and signal/anchor domain, fused to mature chicken ovalbumin (OVA), residues 139-38, resulting in a membrane bound form of ovalbumin. This transgenic construct was injected into C57BL/6J oocytes and founder, 296-1B, was backcrossed to C57BL/6J for 20 generations (C Kurts, H Kosaka et al, 1996). In 2005, transgenic line 296-1B arrived at The Jackson Laboratory, was backcrossed to C57BL/6J one generation and is maintained hemizygote (Tg/0) X noncarrier, wildtype (+/+) sibling (or by the reciprocal cross).
Control Information
| Control | ||
|---|---|---|
| Noncarrier | ||
| Considerations for Choosing Controls | ||
Related Strains
Strains carrying other alleles of Ins2
View Strains carrying other alleles of Ins2 (46 strains)
005145 C57BL/6-Tg(CAG-OVA)916Jen/J 005432 C57BL/6-Tg(Ins2-OVA)307Wehi/WehiJ 005433 C57BL/6-Tg(Ins2-OVA)59Wehi/WehiJ
Phenotype
Phenotype Information
assigned by genotype
Tg(Ins2-TFRC/OVA)296Wehi/0
involves: C57BL/6
- mortality/aging
- increased sensitivity to induced morbidity/mortality
- 75% of mice injected with Tg(TcraTcrb)1100Mjb CD8+ T cells from a Rag1 null mouse and anti-ovalbumin IgG die by day 47 (MGI Ref ID J:122114)
- immune system phenotype
- abnormal CD8-positive T cell morphology
- 3 days following injection of OT-1 cells into transgenic animal, OVA-specific CD*+ T cells show activation and 50% of the cells have proliferated in a BrdU assay; injected non-transgenic animals show considerably less activation or proliferation (MGI Ref ID J:98589)
- abnormal leukocyte migration
- injection of OVA-specific CD8+ T cell from OT-1 mice into transgenic female mice results in a 2- to 6-fold higher proportion of OT-1 CD8+ T cells/total CD8+ T cells in the kidney and pancreatic lymph nodes compared with mesenteric, inguinal or cervical lymph nodes or the spleen, while no accumulation of OT-1 CD8+ T cells is seen in non transgenic animals (MGI Ref ID J:98589)
- decreased interferon-gamma secretion
- mice treated with Tg(TcraTcrb)1100Mjb CD8+ T cells from a Rag1 null mouse without anti-ovalbumin IgG exhibit an IFN-gamma production that is decreased 3-fold compared to in similarly treated Tg(Ins2-TFRC/OVA)296Wehi C3tm1Crr/C3tm1Crrmice (MGI Ref ID J:122114)
- increased susceptibility to autoimmune diabetes
- mice injected with Tg(TcraTcrb)1100Mjb CD8+ T cells from a Rag1 null mouse and anti-ovalbumin IgG exhibit increased incidence of diabetes compared to mice receiving Tg(TcraTcrb)1100Mjb CD8+ T cells alone (MGI Ref ID J:122114)
- hematopoietic system phenotype
- abnormal CD8-positive T cell morphology
- 3 days following injection of OT-1 cells into transgenic animal, OVA-specific CD*+ T cells show activation and 50% of the cells have proliferated in a BrdU assay; injected non-transgenic animals show considerably less activation or proliferation (MGI Ref ID J:98589)
- cellular phenotype
- abnormal leukocyte migration
- injection of OVA-specific CD8+ T cell from OT-1 mice into transgenic female mice results in a 2- to 6-fold higher proportion of OT-1 CD8+ T cells/total CD8+ T cells in the kidney and pancreatic lymph nodes compared with mesenteric, inguinal or cervical lymph nodes or the spleen, while no accumulation of OT-1 CD8+ T cells is seen in non transgenic animals (MGI Ref ID J:98589)
This mouse can be used to support research in many areas including:
Immunology, Inflammation and Autoimmunity Research
Autoimmunity
Type 1 Diabetes
CD Antigens, Antigen Receptors, and Histocompatibility Markers
Research Tools
Diabetes and Obesity Research
Immunology and Inflammation Research
T Cell Receptor Transgenics
Genes & Alleles
Gene & Allele Information provided by MGI
| Allele Symbol | Tg(Ins2-TFRC/OVA)296Wehi | ||
|---|---|---|---|
| Allele Name | transgene insertion 296, Walter and Eliza Hall Institute of Medical Research | ||
| Allele Type | Transgenic (random, expressed) | ||
| Common Name(s) | RIP-mOVA; | ||
| Mutation Made By | William Heath, The Walter and Eliza Hall Institute | ||
| Strain of Origin | C57BL/6 | ||
| Expressed Gene | TFRC, transferrin receptor (p90, CD71), human | ||
| Expressed Gene | OVA, ovalbumin, chicken | ||
| Promoter | Ins2, insulin 2, rat | ||
| General Note | Ovalbumin (OV) is present at high levels in pancreatic beta cells and in kidney proximal tubule cells and at very low levels in testes of transgenic mice. No OV has been detected immunohistologically in any of multiple other tissues examined. Mice expressing both this transgene and Tg(Tcra,Tcrb)1100Mjb (OT-1), which encodes an OV-specific T cell receptor expressed on CD8+ T lymphocytes, exhibit thymic deletion of OT-1 T cells, indicating presence of OV at very low levels in the thymus. Western blot analysis reproducibly measured the pancreatic islet OV content as 2.2 ng/ug of protein. | ||
| Molecular Note | The transgene encodes a fusion protein comprising the carboxy-terminal 118 amino acids of the human transferrin receptor, which include the cytoplasmic tail, membrane-targeting signal and anchor domain of the protein, joined to amino acids 139-385 of mature ovalbumin. Its expression is directed by the rat insulin 2 promoter. [MGI Ref ID J:98589] | ||
Genotyping
Genotyping Information
Genotyping Protocols
Tg(Ins2-OVA), QPCR
Tg(Ins2-OVA), Standard PCR
Helpful Links
Genotyping resources and troubleshooting
References
References provided by MGI
Selected Reference(s)
Kurts C; Heath WR; Carbone FR; Allison J; Miller JF; Kosaka H. 1996. Constitutive class I-restricted exogenous presentation of self antigens in vivo. J Exp Med 184(3):923-30. [PubMed: 9064352] [MGI Ref ID J:98589]
Additional References
Tg(Ins2-TFRC/OVA)296Wehi relatedAnderson MS; Venanzi ES; Chen Z; Berzins SP; Benoist C; Mathis D. 2005. The cellular mechanism of Aire control of T cell tolerance. Immunity 23(2):227-39. [PubMed: 16111640] [MGI Ref ID J:100515]
Attridge K; Wang CJ; Wardzinski L; Kenefeck R; Chamberlain JL; Manzotti C; Kopf M; Walker LS. 2012. IL-21 inhibits T cell IL-2 production and impairs Treg homeostasis. Blood 119(20):4656-64. [PubMed: 22442347] [MGI Ref ID J:185168]
Belz GT; Vremec D; Febbraio M; Corcoran L; Shortman K; Carbone FR; Heath WR. 2002. CD36 is differentially expressed by CD8+ splenic dendritic cells but is not required for cross-presentation in vivo. J Immunol 168(12):6066-70. [PubMed: 12055215] [MGI Ref ID J:123014]
Birnberg T; Bar-On L; Sapoznikov A; Caton ML; Cervantes-Barragan L; Makia D; Krauthgamer R; Brenner O; Ludewig B; Brockschnieder D; Riethmacher D; Reizis B; Jung S. 2008. Lack of conventional dendritic cells is compatible with normal development and T cell homeostasis, but causes myeloid proliferative syndrome. Immunity 29(6):986-97. [PubMed: 19062318] [MGI Ref ID J:142682]
Camacho SA; Heath WR; Carbone FR; Sarvetnick N; LeBon A; Karlsson L; Peterson PA; Webb SR. 2001. A key role for ICAM-1 in generating effector cells mediating inflammatory responses. Nat Immunol 2(6):523-9. [PubMed: 11376339] [MGI Ref ID J:69808]
Chen Z; Benoist C; Mathis D. 2005. How defects in central tolerance impinge on a deficiency in regulatory T cells. Proc Natl Acad Sci U S A 102(41):14735-40. [PubMed: 16203996] [MGI Ref ID J:102496]
Ciric B; El-behi M; Cabrera R; Zhang GX; Rostami A. 2009. IL-23 drives pathogenic IL-17-producing CD8+ T cells. J Immunol 182(9):5296-305. [PubMed: 19380776] [MGI Ref ID J:150310]
Clough LE; Wang CJ; Schmidt EM; Booth G; Hou TZ; Ryan GA; Walker LS. 2008. Release from regulatory T cell-mediated suppression during the onset of tissue-specific autoimmunity is associated with elevated IL-21. J Immunol 180(8):5393-401. [PubMed: 18390721] [MGI Ref ID J:134257]
Colonna L; Catalano G; Chew C; D'Agati V; Thomas JW; Wong FS; Schmitz J; Masuda ES; Reizis B; Tarakhovsky A; Clynes R. 2010. Therapeutic targeting of Syk in autoimmune diabetes. J Immunol 185(3):1532-43. [PubMed: 20601600] [MGI Ref ID J:162249]
Danzl NM; Donlin LT; Alexandropoulos K. 2010. Regulation of medullary thymic epithelial cell differentiation and function by the signaling protein Sin. J Exp Med 207(5):999-1013. [PubMed: 20404100] [MGI Ref ID J:161238]
Davey GM; Kurts C; Miller JF; Bouillet P; Strasser A; Brooks AG; Carbone FR; Heath WR. 2002. Peripheral deletion of autoreactive CD8 T cells by cross presentation of self-antigen occurs by a Bcl-2-inhibitable pathway mediated by Bim. J Exp Med 196(7):947-55. [PubMed: 12370256] [MGI Ref ID J:99555]
Davey GM; Starr R; Cornish AL; Burghardt JT; Alexander WS; Carbone FR; Surh CD; Heath WR. 2005. SOCS-1 regulates IL-15-driven homeostatic proliferation of antigen-naive CD8 T cells, limiting their autoimmune potential. J Exp Med 202(8):1099-108. [PubMed: 16216888] [MGI Ref ID J:116818]
Desai DD; Harbers SO; Flores M; Colonna L; Downie MP; Bergtold A; Jung S; Clynes R. 2007. Fc gamma receptor IIB on dendritic cells enforces peripheral tolerance by inhibiting effector T cell responses. J Immunol 178(10):6217-26. [PubMed: 17475849] [MGI Ref ID J:146123]
Edelmann SL; Marconi P; Brocker T. 2011. Peripheral T cells re-enter the thymus and interfere with central tolerance induction. J Immunol 186(10):5612-9. [PubMed: 21471449] [MGI Ref ID J:173094]
Enouz S; Carrie L; Merkler D; Bevan MJ; Zehn D. 2012. Autoreactive T cells bypass negative selection and respond to self-antigen stimulation during infection. J Exp Med 209(10):1769-79. [PubMed: 22987800] [MGI Ref ID J:191273]
Fassett MS; Jiang W; D'Alise AM; Mathis D; Benoist C. 2012. Nuclear receptor Nr4a1 modulates both regulatory T-cell (Treg) differentiation and clonal deletion. Proc Natl Acad Sci U S A 109(10):3891-6. [PubMed: 22345564] [MGI Ref ID J:182146]
Gallegos AM; Bevan MJ. 2004. Central tolerance to tissue-specific antigens mediated by direct and indirect antigen presentation. J Exp Med 200(8):1039-49. [PubMed: 15492126] [MGI Ref ID J:99681]
Gray DH; Kupresanin F; Berzins SP; Herold MJ; O'Reilly LA; Bouillet P; Strasser A. 2012. The BH3-Only Proteins Bim and Puma Cooperate to Impose Deletional Tolerance of Organ-Specific Antigens. Immunity 37(3):451-62. [PubMed: 22960223] [MGI Ref ID J:187669]
Hanninen A; Nurmela R; Maksimow M; Heino J; Jalkanen S; Kurts C. 2007. Islet beta-cell-specific T cells can use different homing mechanisms to infiltrate and destroy pancreatic islets. Am J Pathol 170(1):240-50. [PubMed: 17200197] [MGI Ref ID J:117052]
Harbers SO; Crocker A; Catalano G; D'Agati V; Jung S; Desai DD; Clynes R. 2007. Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance. J Clin Invest 117(5):1361-9. [PubMed: 17446931] [MGI Ref ID J:122114]
Hoglund P; Mintern J; Waltzinger C; Heath W; Benoist C; Mathis D. 1999. Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell antigens in the pancreatic lymph nodes. J Exp Med 189(2):331-9. [PubMed: 9892615] [MGI Ref ID J:52940]
Irla M; Guerri L; Guenot J; Serge A; Lantz O; Liston A; Imhof BA; Palmer E; Reith W. 2012. Antigen recognition by autoreactive CD4(+) thymocytes drives homeostasis of the thymic medulla. PLoS One 7(12):e52591. [PubMed: 23300712] [MGI Ref ID J:195832]
Irla M; Hugues S; Gill J; Nitta T; Hikosaka Y; Williams IR; Hubert FX; Scott HS; Takahama Y; Hollander GA; Reith W. 2008. Autoantigen-specific interactions with CD4+ thymocytes control mature medullary thymic epithelial cell cellularity. Immunity 29(3):451-63. [PubMed: 18799151] [MGI Ref ID J:139647]
Knoechel B; Lohr J; Kahn E; Bluestone JA; Abbas AK. 2005. Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med 202(10):1375-86. [PubMed: 16287710] [MGI Ref ID J:118848]
Kurts C; Carbone FR; Barnden M; Blanas E; Allison J; Heath WR; Miller JF. 1997. CD4+ T cell help impairs CD8+ T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity. J Exp Med 186(12):2057-62. [PubMed: 9396776] [MGI Ref ID J:99686]
Kurts C; Klebba I; Davey GM; Koch KM; Miller JF; Heath WR; Floege J. 2001. Kidney protection against autoreactive CD8(+) T cells distinct from immunoprivilege and sequestration. Kidney Int 60(2):664-71. [PubMed: 11473649] [MGI Ref ID J:99684]
Kurts C; Kosaka H; Carbone FR; Miller JF; Heath WR. 1997. Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells. J Exp Med 186(2):239-45. [PubMed: 9221753] [MGI Ref ID J:99687]
Kurts C; Miller JF; Subramaniam RM; Carbone FR; Heath WR. 1998. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J Exp Med 188(2):409-14. [PubMed: 9670054] [MGI Ref ID J:99560]
Kurts C; Sutherland RM; Davey G; Li M; Lew AM; Blanas E; Carbone FR; Miller JF; Heath WR. 1999. CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc Natl Acad Sci U S A 96(22):12703-7. [PubMed: 10535986] [MGI Ref ID J:99559]
Lei Y; Ripen AM; Ishimaru N; Ohigashi I; Nagasawa T; Jeker LT; Bosl MR; Hollander GA; Hayashi Y; Malefyt Rde W; Nitta T; Takahama Y. 2011. Aire-dependent production of XCL1 mediates medullary accumulation of thymic dendritic cells and contributes to regulatory T cell development. J Exp Med 208(2):383-94. [PubMed: 21300913] [MGI Ref ID J:176844]
Liu X; Alexiou M; Martin-Orozco N; Chung Y; Nurieva RI; Ma L; Tian Q; Kollias G; Lu S; Graf D; Dong C. 2009. Cutting edge: A critical role of B and T lymphocyte attenuator in peripheral T cell tolerance induction. J Immunol 182(8):4516-20. [PubMed: 19342624] [MGI Ref ID J:147751]
Lohr J; Knoechel B; Kahn EC; Abbas AK. 2004. Role of B7 in T cell tolerance. J Immunol 173(8):5028-35. [PubMed: 15470046] [MGI Ref ID J:93703]
Lohr J; Knoechel B; Wang JJ; Villarino AV; Abbas AK. 2006. Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease. J Exp Med 203(13):2785-91. [PubMed: 17130300] [MGI Ref ID J:124600]
Mamchak AA; Thien CB; Dagger SA; Lyandres J; Jiang S; Langdon WY; DeFranco AL. 2010. Unaltered negative selection and Treg development of self-reactive thymocytes in TCR transgenic Fyn-deficient mice. Eur J Immunol 40(2):539-47. [PubMed: 19904769] [MGI Ref ID J:157790]
McGargill MA; Ch'en IL; Katayama CD; Pages G; Pouyssegur J; Hedrick SM. 2009. Cutting edge: Extracellular signal-related kinase is not required for negative selection of developing T cells. J Immunol 183(8):4838-42. [PubMed: 19801509] [MGI Ref ID J:153582]
McKenzie MD; Dudek NL; Mariana L; Chong MM; Trapani JA; Kay TW; Thomas HE. 2006. Perforin and Fas induced by IFN{gamma} and TNF{alpha} mediate beta cell death by OT-I CTL. Int Immunol 18(6):837-46. [PubMed: 16574667] [MGI Ref ID J:109099]
Miska J; Bas E; Devarajan P; Chen Z. 2012. Autoimmunity-mediated antitumor immunity: Tumor as an immunoprivileged self. Eur J Immunol 42(10):2584-96. [PubMed: 22777737] [MGI Ref ID J:188006]
Nitta T; Nitta S; Lei Y; Lipp M; Takahama Y. 2009. CCR7-mediated migration of developing thymocytes to the medulla is essential for negative selection to tissue-restricted antigens. Proc Natl Acad Sci U S A 106(40):17129-33. [PubMed: 19805112] [MGI Ref ID J:153692]
Ouyang W; Beckett O; Ma Q; Li MO. 2010. Transforming growth factor-beta signaling curbs thymic negative selection promoting regulatory T cell development. Immunity 32(5):642-53. [PubMed: 20471291] [MGI Ref ID J:160693]
Qureshi OS; Zheng Y; Nakamura K; Attridge K; Manzotti C; Schmidt EM; Baker J; Jeffery LE; Kaur S; Briggs Z; Hou TZ; Futter CE; Anderson G; Walker LS; Sansom DM. 2011. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332(6029):600-3. [PubMed: 21474713] [MGI Ref ID J:171354]
Siemens DR; Elzey BD; Lubaroff DM; Bohlken C; Jensen RJ; Swanson AK; Ratliff TL. 2001. Cutting edge: restoration of the ability to generate CTL in mice immune to adenovirus by delivery of virus in a collagen-based matrix. J Immunol 166(2):731-5. [PubMed: 11145643] [MGI Ref ID J:99685]
Snelgrove SL; Kausman JY; Lo C; Lo C; Ooi JD; Coates PT; Hickey MJ; Holdsworth SR; Kurts C; Engel DR; Kitching AR. 2012. Renal dendritic cells adopt a pro-inflammatory phenotype in obstructive uropathy to activate T cells but do not directly contribute to fibrosis. Am J Pathol 180(1):91-103. [PubMed: 22079432] [MGI Ref ID J:180211]
Su MA; Giang K; Zumer K; Jiang H; Oven I; Rinn JL; Devoss JJ; Johannes KP; Lu W; Gardner J; Chang A; Bubulya P; Chang HY; Peterlin BM; Anderson MS. 2008. Mechanisms of an autoimmunity syndrome in mice caused by a dominant mutation in Aire. J Clin Invest 118(5):1712-26. [PubMed: 18414681] [MGI Ref ID J:135154]
Suen AY; Baldwin TA. 2012. Proapoptotic protein Bim is differentially required during thymic clonal deletion to ubiquitous versus tissue-restricted antigens. Proc Natl Acad Sci U S A :. [PubMed: 22215602] [MGI Ref ID J:179928]
Sutherland AP; Joller N; Michaud M; Liu SM; Kuchroo VK; Grusby MJ. 2013. IL-21 Promotes CD8+ CTL Activity via the Transcription Factor T-bet. J Immunol 190(8):3977-84. [PubMed: 23479229] [MGI Ref ID J:194899]
Takeuchi A; Itoh Y; Takumi A; Ishihara C; Arase N; Yokosuka T; Koseki H; Yamasaki S; Takai Y; Miyoshi J; Ogasawara K; Saito T. 2009. CRTAM confers late-stage activation of CD8+ T cells to regulate retention within lymph node. J Immunol 183(7):4220-8. [PubMed: 19752223] [MGI Ref ID J:152770]
Walker LS; Chodos A; Eggena M; Dooms H; Abbas AK. 2003. Antigen-dependent proliferation of CD4+ CD25+ regulatory T cells in vivo. J Exp Med 198(2):249-58. [PubMed: 12874258] [MGI Ref ID J:118775]
Xie Y; Zhang H; Li W; Deng Y; Munegowda MA; Chibbar R; Qureshi M; Xiang J. 2010. Dendritic cells recruit T cell exosomes via exosomal LFA-1 leading to inhibition of CD8+ CTL responses through downregulation of peptide/MHC class I and Fas ligand-mediated cytotoxicity. J Immunol 185(9):5268-78. [PubMed: 20881190] [MGI Ref ID J:165185]
Ye Z; Ahmed KA; Huang J; Xie Y; Munegowda MA; Xiang J. 2008. T cell precursor frequency differentially affects CTL responses under different immune conditions. Biochem Biophys Res Commun 367(2):427-34. [PubMed: 18178159] [MGI Ref ID J:131030]
Zehn D; Bevan MJ. 2006. T cells with low avidity for a tissue-restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity. Immunity 25(2):261-70. [PubMed: 16879996] [MGI Ref ID J:113466]
Zelenay S; Keller AM; Whitney PG; Schraml BU; Deddouche S; Rogers NC; Schulz O; Sancho D; Reis e Sousa C. 2012. The dendritic cell receptor DNGR-1 controls endocytic handling of necrotic cell antigens to favor cross-priming of CTLs in virus-infected mice. J Clin Invest 122(5):1615-27. [PubMed: 22505458] [MGI Ref ID J:184531]
Zhu M; Chin RK; Tumanov AV; Liu X; Fu YX. 2007. Lymphotoxin beta receptor is required for the migration and selection of autoreactive T cells in thymic medulla. J Immunol 179(12):8069-75. [PubMed: 18056347] [MGI Ref ID J:155040]
Health & husbandry
Health & Colony Maintenance Information
Animal Health Reports
Room Number FGB29
Colony Maintenance
Mating System +/+ sibling x Hemizygote (Female x Male) 16-APR-08 Diet Information LabDiet® 5K52/5K67
Pricing and Purchasing
Pricing, Supply Level & Notes, Controls
| Pricing for USA, Canada and Mexico shipping destinations |
|
Live Mice
Price per mouse (US dollars $) Gender Genotypes Provided Individual Mouse $177.00 Female or Male Hemizygous for Tg(Ins2-TFRC/OVA)296Wehi
Price per Pair (US dollars $) Pair Genotype $241.00 Hemizygous for Tg(Ins2-TFRC/OVA)296Wehi x Noncarrier $241.00 Noncarrier x Hemizygous for Tg(Ins2-TFRC/OVA)296Wehi $354.00 Hemizygous for Tg(Ins2-TFRC/OVA)296Wehi x Hemizygous for Tg(Ins2-TFRC/OVA)296Wehi Standard Supply
Repository-Live. Repository-Live represents an exclusive set of over 1500 unique mouse models maintained at The Jackson Laboratory to support a vast array of research areas. The breeding colonies for Repository Strains provide mice for both large and small orders and fluctuate in size depending on current demand for each strain. Repository-live orders are treated as custom orders. Within 2 business days, we respond to each availability inquiry or order with various delivery options. Repository Strains typically are delivered at 4 to 8 weeks of age and will not exceed 12 weeks of age on the day of shipping.
| Pricing for International shipping destinations |
|
Live Mice
Price per mouse (US dollars $) Gender Genotypes Provided Individual Mouse $230.10 Female or Male Hemizygous for Tg(Ins2-TFRC/OVA)296Wehi
Price per Pair (US dollars $) Pair Genotype $313.30 Hemizygous for Tg(Ins2-TFRC/OVA)296Wehi x Noncarrier $313.30 Noncarrier x Hemizygous for Tg(Ins2-TFRC/OVA)296Wehi $460.20 Hemizygous for Tg(Ins2-TFRC/OVA)296Wehi x Hemizygous for Tg(Ins2-TFRC/OVA)296Wehi Standard Supply
Repository-Live. Repository-Live represents an exclusive set of over 1500 unique mouse models maintained at The Jackson Laboratory to support a vast array of research areas. The breeding colonies for Repository Strains provide mice for both large and small orders and fluctuate in size depending on current demand for each strain. Repository-live orders are treated as custom orders. Within 2 business days, we respond to each availability inquiry or order with various delivery options. Repository Strains typically are delivered at 4 to 8 weeks of age and will not exceed 12 weeks of age on the day of shipping.
|
|
|
Standard Supply
Repository-Live. Repository-Live represents an exclusive set of over 1500 unique mouse models maintained at The Jackson Laboratory to support a vast array of research areas. The breeding colonies for Repository Strains provide mice for both large and small orders and fluctuate in size depending on current demand for each strain. Repository-live orders are treated as custom orders. Within 2 business days, we respond to each availability inquiry or order with various delivery options. Repository Strains typically are delivered at 4 to 8 weeks of age and will not exceed 12 weeks of age on the day of shipping.
Control Information
| Control | ||
|---|---|---|
| Noncarrier | ||
| Considerations for Choosing Controls | ||
| Control Pricing Information for Genetically Engineered Mutant Strains. | ||
Payment Terms and Conditions
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
See Terms of Use tab for General Terms and Conditions
The Jackson Laboratory's Genotype Promise
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form
Terms of Use
Terms of Use
General Terms and Conditions
Contact information
General inquiries regarding Terms of UseContracts Administration
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
JAX® Mice, Products & Services Conditions of Use
"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.No Warranty
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.
No Liability
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.